Home  >  News
Eppen_Research3neo_Feb26
you can get e-magazine links on WhatsApp. Click here
News
  Median Technologies collaborates with Tempus to expand access to Eyonis LCS software as a medical device in United States,   February 14, 2026
  Galderma launches OBT hyaluronic acid injectables Restylane Defyne and Refyne in Japan,   February 12, 2026
  OneSource and Hikma Pharma partnership secures approval to commercialise generic version of Ozempic in Saudi Arabia,   February 11, 2026
  Akums receives UK MHRA marketing approval for rivaroxaban,   February 10, 2026
  Breckenridge Pharma collaborates with Medichem to expand Breckenridge's injectable biz line to the US hospital channel,   February 07, 2026
  Lupin introduces topiramate extended-release capsules in US market,   February 05, 2026
  Natera submits premarket approval to US FDA for Signatera CDx for detection of MRD in patients with muscle-invasive bladder cancer,   February 04, 2026
  Alvotech inks supply and commercialization pacts with Sandoz covering multiple biosimilar candidates in Canada, Australia & New Zealand,   February 03, 2026
  Tenacia Biopharmac & Golden Age Health partner to commercialize Ztalmy for CDKL5 deficiency disorder in Mainland China,   February 03, 2026
  Lupin introduces dasatinib tablets in the United States,   February 02, 2026
  EMA committee recommends marketing approval for UCB’s Kygevvi to treat thymidine kinase 2 deficiency,   February 02, 2026
  EMA committee recommends conditional marketing authorization to Sanofi’s Rezurock to treat chronic graft-vs-host disease,   February 02, 2026
  Bracco Imaging announces European Commission extended marketing authorisation for Vueway in EU for use in paediatric patients under 2 years of age,   January 28, 2026
  IntraBio’s Aqneursa receives European Commission’s marketing approval for treatment of Niemann-Pick Type C disease,   January 24, 2026
  AGC Biologics receives US and EU marketing approvals for Waskyra to treat Wiskott-Aldrich syndrome,   January 22, 2026
  EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer,   January 20, 2026
  European Commission grants marketing approval for Eylea 8 mg to treat macular edema following RVO, including branch, central and hemiretinal vein occlusion,   January 19, 2026
  In 2025 EMA recommends 104 new medicines for marketing approval; 38 had a new active substance,   January 19, 2026
  Venus Remedies receives Indonesian marketing approval for combination antibiotic, ceftazidime+avibactam,   January 15, 2026
  Alphatec Holdings, Theradaptive ink marketing partnership for breakthrough regenerative technology in spinal fusion,   January 14, 2026

  • Results Found: 7167
  • 1
    •  
  • 2
    •  
  • 3
    •  
  • 4
    •  
  • 5
    •  
  • Go to
  • Total Number of Pages: 359
 Back
 
CP_CPHI_Korea2026
ChemExpo_India_2026
ASIA_PHARMA_EXPO_2026
CPHI_Japan26
Ana_Lab_India_2026
PharmaCore_India_2026
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram